Psychiatric Annals

CME Article 

New Drug Treatments for ADHD

Keith McBurnett, PhD; Nicholas Weiss, MD

Abstract

Several new treatments for attention-deficit/hyperactivity disorder have been developed in recent years. For the most part, new commercial products during this time have been reformulations of existing molecules differentiated by delivery systems, with the intent of extending the duration of effect, reducing the abuse liability, or otherwise adding features of potential clinical benefit.

ABOUT THE AUTHORS

Keith McBurnett, PhD; and Nicholas Weiss, MD, are with the Department of Psychiatry, University of California, San Francisco.

Address correspondence to: Keith McBurnett, PhD, UCSF-LPPI Room 140, 401 Parnassus Avenue, San Francisco, CA 94143; or e-mail: keithm@lppi.ucsf.edu.

Dr. McBurnett has disclosed the following relevant financial relationships: Eli Lilly and Shire; Consultant; and Eli Lilly, Otsuka, and Shire: Contracted research. Dr. Weiss has disclosed no relevant financial relationships.

EDUCATIONAL OBJECTIVES

  1. Describe key aspects of newer stimulant preparations, including their novel delivery systems and their low potential for abuse and diversion.
  2. Identify the risks, benefits and indications for extended-release formulations of alpha-agonists in the treatment of attention-deficit/hyperactivity disorder (ADHD).
  3. Describe several investigational agents for ADHD, including their rationale and novel mechanisms of action.

Abstract

Several new treatments for attention-deficit/hyperactivity disorder have been developed in recent years. For the most part, new commercial products during this time have been reformulations of existing molecules differentiated by delivery systems, with the intent of extending the duration of effect, reducing the abuse liability, or otherwise adding features of potential clinical benefit.

ABOUT THE AUTHORS

Keith McBurnett, PhD; and Nicholas Weiss, MD, are with the Department of Psychiatry, University of California, San Francisco.

Address correspondence to: Keith McBurnett, PhD, UCSF-LPPI Room 140, 401 Parnassus Avenue, San Francisco, CA 94143; or e-mail: keithm@lppi.ucsf.edu.

Dr. McBurnett has disclosed the following relevant financial relationships: Eli Lilly and Shire; Consultant; and Eli Lilly, Otsuka, and Shire: Contracted research. Dr. Weiss has disclosed no relevant financial relationships.

EDUCATIONAL OBJECTIVES

  1. Describe key aspects of newer stimulant preparations, including their novel delivery systems and their low potential for abuse and diversion.
  2. Identify the risks, benefits and indications for extended-release formulations of alpha-agonists in the treatment of attention-deficit/hyperactivity disorder (ADHD).
  3. Describe several investigational agents for ADHD, including their rationale and novel mechanisms of action.

10.3928/00485713-20101221-04

Sign up to receive

Journal E-contents